HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC)

Authors :: Ace J. Hatch
Kouros Owzar
Alexander B. Sibley
Philip Quirke
Herbert Hurwitz
Andrew B. Nixon
Susan D. Richman
Matthew T. Seymour
Chen Jiang
Faye Elliott
Jenny F. Seligmann
Jenny Barrett
Bart Jacobs
Source :: Journal of Clinical Oncology. 33:3583-3583
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 3583 Background: EGFR pathway activation is important in aCRC, but EGFR expression is not predictive for anti-EGFR drug efficacy. Signalling occurs across ErbB receptors and EGFR may mediate oncoge...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Egfr expression
Advanced colorectal cancer
Efficacy
ErbB Receptors
Internal medicine
medicine
Panitumumab
Biomarker (medicine)
Egfr signaling
business
medicine.drug

Tools